Concepedia

Publication | Closed Access

First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer

DOI

42

Citations

33

References

2020

Year

Xiuhua Weng, Xiaoting Huang, Hongchao Li, Shen Lin, Xin Rao, Xianzhong Guo, Pinfang Huang
American Journal of Clinical Oncology

Abstract

AnP is not a cost-effective choice as the first-line treatment for advanced triple-negative breast cancer in the United States and China.

References

YearCitations

Page 1